90 related articles for article (PubMed ID: 21930117)
21. Trans-3'-hydroxycotinine O- and N-glucuronidations in human liver microsomes.
Yamanaka H; Nakajima M; Katoh M; Kanoh A; Tamura O; Ishibashi H; Yokoi T
Drug Metab Dispos; 2005 Jan; 33(1):23-30. PubMed ID: 15470160
[TBL] [Abstract][Full Text] [Related]
22. Interaction of cytochrome P450 3A4 and UDP-glucuronosyltransferase 2B7: evidence for protein-protein association and possible involvement of CYP3A4 J-helix in the interaction.
Takeda S; Ishii Y; Iwanaga M; Nurrochmad A; Ito Y; Mackenzie PI; Nagata K; Yamazoe Y; Oguri K; Yamada H
Mol Pharmacol; 2009 Apr; 75(4):956-64. PubMed ID: 19158361
[TBL] [Abstract][Full Text] [Related]
23. Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs.
Jin C; Miners JO; Lillywhite KJ; Mackenzie PI
J Pharmacol Exp Ther; 1993 Jan; 264(1):475-9. PubMed ID: 8423545
[TBL] [Abstract][Full Text] [Related]
24. In vitro characterisation of human renal and hepatic frusemide glucuronidation and identification of the UDP-glucuronosyltransferase enzymes involved in this pathway.
Kerdpin O; Knights KM; Elliot DJ; Miners JO
Biochem Pharmacol; 2008 Jul; 76(2):249-57. PubMed ID: 18541222
[TBL] [Abstract][Full Text] [Related]
25. The caudal-related homeodomain protein Cdx2 and hepatocyte nuclear factor 1alpha cooperatively regulate the UDP-glucuronosyltransferase 2B7 gene promoter.
Gregory PA; Gardner-Stephen DA; Rogers A; Michael MZ; Mackenzie PI
Pharmacogenet Genomics; 2006 Jul; 16(7):527-36. PubMed ID: 16788384
[TBL] [Abstract][Full Text] [Related]
26. Extensive protein-protein interactions involving UDP-glucuronosyltransferase (UGT) 2B7 in human liver microsomes.
Fujiwara R; Itoh T
Drug Metab Pharmacokinet; 2014; 29(3):259-65. PubMed ID: 24366439
[TBL] [Abstract][Full Text] [Related]
27. The first aspartic acid of the DQxD motif for human UDP-glucuronosyltransferase 1A10 interacts with UDP-glucuronic acid during catalysis.
Xiong Y; Patana AS; Miley MJ; Zielinska AK; Bratton SM; Miller GP; Goldman A; Finel M; Redinbo MR; Radominska-Pandya A
Drug Metab Dispos; 2008 Mar; 36(3):517-22. PubMed ID: 18048489
[TBL] [Abstract][Full Text] [Related]
28. Glucuronidation of opioids, carboxylic acid-containing drugs, and hydroxylated xenobiotics catalyzed by expressed monkey UDP-glucuronosyltransferase 2B9 protein.
Green MD; Bélanger G; Hum DW; Bélanger A; Tephly TR
Drug Metab Dispos; 1997 Dec; 25(12):1389-94. PubMed ID: 9394029
[TBL] [Abstract][Full Text] [Related]
29. Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A6 enzymes.
Hanioka N; Takeda Y; Jinno H; Tanaka-Kagawa T; Naito S; Koeda A; Shimizu T; Nomura M; Narimatsu S
Chem Biol Interact; 2006 Dec; 164(1-2):136-45. PubMed ID: 17027947
[TBL] [Abstract][Full Text] [Related]
30. Altered AZT (3'-azido-3'-deoxythymidine) glucuronidation kinetics in liver microsomes as an explanation for underprediction of in vivo clearance: comparison to hepatocytes and effect of incubation environment.
Engtrakul JJ; Foti RS; Strelevitz TJ; Fisher MB
Drug Metab Dispos; 2005 Nov; 33(11):1621-7. PubMed ID: 16049128
[TBL] [Abstract][Full Text] [Related]
31. Spironolactone and canrenone inhibit UGT2B7-catalyzed human liver and kidney microsomal aldosterone 18beta-glucuronidation: a potential drug interaction.
Knights KM; Bowalgaha K; Miners JO
Drug Metab Dispos; 2010 Jul; 38(7):1011-4. PubMed ID: 20304966
[TBL] [Abstract][Full Text] [Related]
32. Human UDP-glucuronosyltransferase 2B7.
Radominska-Pandya A; Little JM; Czernik PJ
Curr Drug Metab; 2001 Sep; 2(3):283-98. PubMed ID: 11513331
[TBL] [Abstract][Full Text] [Related]
33. Crystal structure of the cofactor-binding domain of the human phase II drug-metabolism enzyme UDP-glucuronosyltransferase 2B7.
Miley MJ; Zielinska AK; Keenan JE; Bratton SM; Radominska-Pandya A; Redinbo MR
J Mol Biol; 2007 Jun; 369(2):498-511. PubMed ID: 17442341
[TBL] [Abstract][Full Text] [Related]
34. 3D-QSAR studies on UDP-glucuronosyltransferase 2B7 substrates using the pharmacophore and VolSurf approaches.
Ako R; Dong D; Wu B
Xenobiotica; 2012 Sep; 42(9):891-900. PubMed ID: 22494439
[TBL] [Abstract][Full Text] [Related]
35. N-glycosylation and residue 96 are involved in the functional properties of UDP-glucuronosyltransferase enzymes.
Barbier O; Girard C; Breton R; Bélanger A; Hum DW
Biochemistry; 2000 Sep; 39(38):11540-52. PubMed ID: 10995221
[TBL] [Abstract][Full Text] [Related]
36. Epirubicin upregulates UDP glucuronosyltransferase 2B7 expression in liver cancer cells via the p53 pathway.
Hu DG; Rogers A; Mackenzie PI
Mol Pharmacol; 2014 Jun; 85(6):887-97. PubMed ID: 24682467
[TBL] [Abstract][Full Text] [Related]
37. Heterodimerization of Human UDP-Glucuronosyltransferase 1A9 and UDP-Glucuronosyltransferase 2B7 Alters Their Glucuronidation Activities.
Xue J; Yin J; Nie J; Jiang H; Zhang H; Zeng S
Drug Metab Dispos; 2023 Nov; 51(11):1499-1507. PubMed ID: 37643881
[TBL] [Abstract][Full Text] [Related]
38. Suppression of Cytochrome P450 3A4 Function by UDP-Glucuronosyltransferase 2B7 through a Protein-Protein Interaction: Cooperative Roles of the Cytosolic Carboxyl-Terminal Domain and the Luminal Anchoring Region.
Miyauchi Y; Nagata K; Yamazoe Y; Mackenzie PI; Yamada H; Ishii Y
Mol Pharmacol; 2015 Oct; 88(4):800-12. PubMed ID: 26243732
[TBL] [Abstract][Full Text] [Related]
39. Eudismic analysis of tricyclic sesquiterpenoid alcohols: lead structures for the design of potent inhibitors of the human UDP-glucuronosyltransferase 2B7.
Bichlmaier I; Kurkela M; Siiskonen A; Finel M; Yli-Kauhaluoma J
Bioorg Chem; 2007 Oct; 35(5):386-400. PubMed ID: 17706742
[TBL] [Abstract][Full Text] [Related]
40. Investigation of the Endoplasmic Reticulum Localization of UDP-Glucuronosyltransferase 2B7 with Systematic Deletion Mutants.
Miyauchi Y; Kimura S; Kimura A; Kurohara K; Hirota Y; Fujimoto K; Mackenzie PI; Tanaka Y; Ishii Y
Mol Pharmacol; 2019 May; 95(5):551-562. PubMed ID: 30944207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
